🟢 96/100

This product looks safe

  • Niacinamide: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)
  • 67% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacinamide: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)

Label Data

1 Capsule(s) Serving Size
45 Servings
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

Calories
10 {Calories}
2.5 mg (3125% DV)
📊 20.8× RDA — above typical dose 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 2.5mg
200 mcg (66% DV)
📊 6.7× RDA — above typical dose 📚 26 studies (Tier A: 0, B: 11)
RDA 0.03mg This product: 0.2mg
Vitamin C
112 mg (137% DV)
100 mg (500% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 2.9× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 100mg UL 35mg
200 mcg (286% DV)
📊 3.6× RDA — above typical dose (UL: 0.4 mg) 📚 172 studies (Tier A: 0, B: 67)
RDA 0.055mg This product: 0.2mg UL 0.4mg
📊 Market median: 200.0mg (198 products) 📚 6 studies — no high-quality reviews
This product: 300mg
250 mg
📊 Market median: 500.0mg (283 products) 📚 173 studies (Tier A: 0, B: 62)
This product: 250mg
📊 Market median: 100.0mg (284 products) 📚 10 studies (Tier A: 0, B: 4)
This product: 50mg

Other Ingredients

Gelatin Silicon Dioxide Magnesium Stearate

Label Claims — Verification

All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use As a dietary supplement, 1 or 2 capsules two times daily, or as directed by a healthcare practitioner.

⚠️ Warnings & Precautions

Caution: Not intended for use by pregnant or lactating women.

Diabetics, use only under a physician's supervision. Seek the advice of a health professional before using this product.

Keep out of reach of children.

Do not exceed 400 micrograms of selenium per day from all sources.

Additional Information

IVC-Max provides nutrients that are involved with the utilization of Vitamin C.

Rev. 004

Keep in a cool, dry place, tightly capped.

Product Details

UPC / SKU 7 13947 74160 7
DSLD Entry Date 2015-12-23
Product Type Other Combinations
Form Capsule
DSLD ID 54113
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →